Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease

Lü, Lin; Wang, Ya Nan; Li, Ming Chun; Wang, Hai Bo; Li, Pu; Niu, Wangqiang; Meng, Hua; Yang, Er Li; Zhang, Rui Yan; Zhang, Qi; Zhao, Qiang; Chen, Qiujing; Caterina, Raffaele De; Shen, Wei Feng

doi:10.1093/eurheartj/ehs122

Cited by 29 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2A ]. This finding was consistent with a previous study that examined acute myocardial infarction patients 14 . Notably, a stepwise decrease in the TN levels was found depending on the number of diseased vessels: 11.11 ± 3.27 mg/ml in CAD-negative, 10.41 ± 3.28 mg/ml in one-vessel disease, 9.90 ± 3.03 mg/ml in two-vessel disease, and 9.30 ± 3.84 mg/ml in three-vessel disease.…”

Section: Resultssupporting

confidence: 94%

Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease

Chen

Han

Yan

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

This cross-sectional study tested the hypothesis that decreased serum levels of tetranectin (TN), a regulator of the fibrinolysis and proteolytic system, is associated with the presence and severity of CAD. We conducted a systematic serological and immunohistochemical (IHC) analysis to respectively compare the TN levels in serum and artery samples in CAD patients and healthy controls. Our results showed that serum levels of TN were significantly lower in patients with CAD than in healthy controls. Further analysis via trend tests revealed that serum TN levels correlated with the number of diseased arteries. Besides, the multivariate logistic regression model revealed TN as an independent factor associated with the presence of CAD. Additionally, IHC analysis showed that TN expression was significantly higher in atherosclerotic arteries as compared to healthy control tissues. In conclusion, our study suggests that increased serum TN level is associated with the presence and severity of diseased coronary arteries in patients with stable CAD.

show abstract

Section: Resultssupporting

confidence: 94%

Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease

Chen

Han

Yan

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous clinical trials on restoration of perfusion through collateral growth using growth factors have failed largely because of an overlapping mechanism between arteriogenesis and atherosclerosis. In future, certain protective factors including endogenous soluble RAGE and vasostatin-2 which are decreased in patients with T2DM could be alternative therapeutic targets [ 89 ]. Emerging evidence suggests that microRNAs are implicated in a variety of physiological processes, including glucose homeostasis [ 90 ].…”

Section: Clinical Perspectivementioning

confidence: 99%

Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion

Shen

Ding

Dai

et al. 2018

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

BackgroundThe extent of coronary collateral formation is a primary determinant of the severity of myocardial damage and mortality after coronary artery occlusion. Type 2 diabetes mellitus (T2DM) represents an important risk factor for impaired collateral vessel growth. However, the mechanism of reduced coronary collateralization in type 2 diabetic patients remains unclear.MethodsWith the reference to the recent researches, this review article describes the pathogenic effects of T2DM on collateral development and outlines possible clinical and biochemical markers associated with reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion (CTO).ResultsDiffuse coronary atherosclerosis in T2DM reduces pressure gradient between collateral donor artery and collateral recipient one, limiting collateral vessel growth and function. An interaction between advanced glycation end-products and their receptor activates several intracellular signaling pathways, enhances oxidative stress and aggravates inflammatory process. Diabetic condition decreases pro-angiogenic factors especially vascular endothelial growth factor and other collateral vessel growth related parameters. Numerous clinical and biochemical factors that could possibly attenuate the development of coronary collaterals have been reported. Increased serum levels of glycated albumin, cystatin C, and adipokine C1q tumor necrosis factor related protein 1 were associated with poor coronary collateralization in type 2 diabetic patients with stable coronary artery disease and CTO. Diastolic blood pressure and stenosis severity of the predominant collateral donor artery also play a role in coronary collateral formation.ConclusionsT2DM impairs collateral vessel growth through multiple mechanisms involving arteriogenesis and angiogenesis, and coronary collateral formation in patients with T2DM and CTO is influenced by various clinical, biochemical and angiographic factors. This information provides insights into the understanding of coronary pathophysiology and searching for potential new therapeutic targets in T2DM.

show abstract

“…Pep5 (T 25 -F 39 ) and Pep6 (K 28 -L 42 ) are located in ChgA-derived peptide vasostatin-1 (human ChgA1-76), which can affect the tumor microenvironment by interfering with the signaling triggered by tumor necrosis factor alpha and vascular endothelial growth factor on endothelial cells [20]. Pep14 (L 64 -K 78 ) and Pep16 (K 70 -D 84 ) are located in vasostatin-2 (human ChgA1-113) and vasostatin-1 (human ChgA1-94), suggesting the existence of an anti-inflammatory effect [21]. Pep29 (R 313 -M 327 ) cross over SS-18 (human ChgA304-321) and WE-14 (human ChgA324-337), while WSKM of Pep29 is located in the WE-14 fragment, which was suggested to be a potential epitope for BDC2.5 T cells [10].…”

Section: Discussionmentioning

confidence: 99%

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

Huang

Teng³

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Cancer-associated autoantibodies show promise as sensitive biomarkers for the early detection of cancer. To test the immunogenicity of chromogranin A (ChgA) as a B cell autoantigen and to assess the potential applications of ChgA autoantibodies as novel biomarkers for the diagnosis of non-small cell lung cancer (NSCLC), we developed a high-content peptide microarray using ChgA peptides. Autoantibody profiling was carried out using sera from 168 individuals with NSCLC and 97 healthy controls. We present evidence for the occurrence of autoantibodies to ChgA peptides in patient sera and identified five highly responsive peptides in the NSCLC group using significance analysis of microarray (SAM). Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of NSCLC, suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC. Moreover, the high-content peptide microarray antibody profiling reported in this work provides a powerful tool to visualize the overall B cell response to ChgA peptides and should enable the rapid development of in-depth research into ChgA.

show abstract

Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease

Cited by 29 publications

References 33 publications

Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease

Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease

Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

Contact Info

Product

Resources

About